RAM-ACTIVE-INVESTMENTS
9.7.2020 09:02:08 CEST | Business Wire | Press release
RAM Active Investments SA ("RAM AI"), a systematic asset manager based in Geneva, is launching a fund with the objective to tackle the climate emergency and to provide investors an active strategy with strong ESG standards. RAM AI’s innovative ESG approach is the result of extensive research exploring alternative data thanks to the successful development of the RAM AI Machine Learning (ML) infrastructure.
As the Climate Change emergency continues to grow RAM AI believes its role as an asset manager is to provide investors with a differentiated solution to low-carbon investing. Emmanuel Hauptmann who heads the Systematic Equity research shares: “The RAM ML team has made tremendous advances in building the strategy with the objective to provide a selection of best-in-class, low-carbon companies without compromising performance. ”
While many managers opt for a unidimensional approach to climate change within portfolios by reducing the weight of the worst polluters, RAM AI’s sustainable alpha approach aims to leverage a myriad of ESG and non-ESG data sources to identify the most attractive sustainable return opportunities in each industry. Nicolas Jamet, who leads the research efforts on ESG integration adds: “Our research effort is based on hypothesis testing; understanding how the ESG profile of a given company impacts, not only future stock performance, but also current/future fundamentals and ultimately financial returns.”
Thanks to a robust Machine Learning infrastructure, RAM AI applies a systematic process to select companies combining financial and ESG data, with both structured and unstructured (i.e. news-flow) inputs. To learn more about how AI is used to integrate unstructured ESG news-flow on companies to improve selection, please read our latest publication on the topic: A Natural Language Processing (NLP) based framework for ESG Integration .
RAM AI is excited about this development and sees it as a cornerstone to its commitment and long-term alignment towards the SDGs. The cross-fertilisation of ideas within the RAM research team will lead to more innovation across products using ESG data and NLP techniques to improve the alpha prediction.
The Fund is available in a UCITS format as of the 9th of July 2020 to investors in Luxembourg, Germany, Denmark, Spain, Netherlands, Italy, Norway, Sweden, Portugal, United Kingdom, Singapore and Japan. The fund is currently in the process of being registered in Switzerland. RAM AI will also aim to offset the Fund’s (low) carbon emissions (Scopes I and II) using carbon compensation certificates (CERs) in accordance with the Clean Development Mechanism (CDM) rules at no additional cost to investors.
RAM Active Investments
RAM Active Investments is a systematic asset manager with a long experience in creating value for its customers in any market condition. Research is at the heart of our disciplined approach to investment, which enables us to identify and continually exploit new market inefficiencies by adopting the latest innovative technologies.
Founded in 2007 by Thomas de Saint-Seine, Maxime Botti and Emmanuel Hauptmann, RAM Active Investments, an affiliate of Mediobanca Group since March 2018, operates independently worldwide with more than 40 employees and four offices in Geneva (headquarter), Zurich, Luxembourg and Milan. Asset under Management of USD 3,1 billion as of end of December 2019.
To find out more about RAM Active Investments visit the website ram-ai.com or follow us on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005314/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom